China SXT Pharmaceuticals, Inc. (SXTC) Return on equity 2017–2026
China SXT Pharmaceuticals, Inc. (SXTC) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-20.9%FY2026 · since FY2017: 64.0% → -20.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | -20.9% | +0.5 pp |
| FY2025 | -21.4% | +0.8 pp |
| FY2024 | -22.2% | +18.2 pp |
| FY2023 | -40.4% | -4.7 pp |
| FY2022 | -35.7% | -18.4 pp |
| FY2021 | -17.2% | +92.2 pp |
| FY2020 | -109.4% | -123.3 pp |
| FY2019 | 13.9% | -22.3 pp |
| FY2018 | 36.1% | -27.8 pp |
| FY2017 | 64.0% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice